Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SyntheX Labs is developing a small-molecule molecular glue targeting STAG1 for the treatment of cancer. Discovered using the company's proprietary ToRNeDO platform, this program leverages the concept of synthetic lethality. STAG1 is a paralog of STAG2, both of which are components of the cohesin complex. In many cancers, STAG2 is mutated or lost; research indicates that these STAG2-deficient cells become uniquely dependent on STAG1 for survival. By promoting the degradation or functional modulation of STAG1 through a molecular glue mechanism, the drug aims to selectively kill STAG2-deficient tumor cells while sparing healthy tissue. The program is currently in the screening and discovery phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on STAG1 molecular glue.